Trials Sponsors Conditions Drugs Pricing

Conditions

Colorectal Cancer Screening

Outcome Measures

Primary Outcomes (2)

Sensitivity for CRC of the FirstSight test
30 days
Specificity of the FirstSight test
30 days

Study Arms (2)

Cohort A

Cohort A will include subjects with a recent diagnosis of colorectal cancer and/or advanced adenoma requiring additional endoscopic or surgical resection (surgery).

Diagnostic Test: FirstSight blood test

Cohort B

Cohort B will include subjects undergoing routine screening colonoscopies will be enrolled in the screening cohort.

Diagnostic Test: FirstSight blood test

Interventions

FirstSight blood testDiagnostic test

FirstSight blood test for colorectal cancer screening

Cohort ACohort B

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age45 Years - 80 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Cohort A: This cohort will include subjects with a recent diagnosis of colorectal cancer or advanced adenoma requiring surgical resection. Cohort B: This cohort will include subjects undergoing routine screening colonoscopies for colorectal cancer as part of their regular medical assessment regimen.

You may qualify if:

To enroll in Cohort A, a subject must:

Sponsors & Collaborators

CellMax Life
Industrylead

Study Sites (15)

CellMax Site A

Huntsville, Alabama, 35801, United States

ACTIVE_NOT_RECRUITING

CellMax Site O

Chula Vista, California, 91910, United States

RECRUITING

CellMax Site L

Lancaster, California, 93534, United States

RECRUITING

CellMax Site J

Tustin, California, 92780, United States

Study Officials

Rui Mei, PhD
CellMax Life
STUDY DIRECTOR

Central Study Contacts

Ben Hsieh, PhD

CONTACT

650-814-8088 ben@cellmaxlife.com

Stephen Su, PhD

CONTACT

408-887-7640

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

November 9, 2021

First Posted

November 19, 2021

Study Start

December 15, 2020

Actual (reported)

Primary Completion

September 30, 2022

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (2)

Cohort A

Cohort B

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (15)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (2)

Cohort A

Cohort B

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (15)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations